Infectious Disease

I have admitted infants to the hospital every winter for 40 years, yet I still don't have good answers for anxious parents watching their child struggling to breathe.

RSV is back for the 2022-23 respiratory virus season and is unfamiliar to many. Click through this quick collection of myths already in circulation to prepare.

Topline phase 3 trial data showed 81.8% efficacy for the maternal vaccine against severe RSV-related illness in infants from birth through first 90 days of life.

The GSK RSV vaccine candidate has received favorable international regulatory attention which may be an auspicious sign for the US.

Your daily dose of clinical news you may have missed.

Your daily dose of clinical news you may have missed.

Efficacy of the RZV vaccine against herpes zoster infection remained >80% in a long-term follow-up study representing 10 years since initial immunization.

IDWeek 2022: New data show a greater than 60% reduction in acute exacerbations and need for antibiotics in patients with CS who used fluticasone propionate nasal spray.

The overall US COVID-19 vaccination picture has both bright spots and dark areas. Get a quick look at details from the most recent KFF Vaccine Monitor survey.

The high-dose influenza vaccines provided greater relative vaccine effectiveness/efficacy vs standard dose in a cohort of more than 45 million.

AAFP Board Chair Ransone points to recent data that show two-thirds of long COVID patients are already treated in primary care settings.

It is clear that COVID-19 comes in waves, but it's too soon in the life of the virus to predict patterns, Ransone says. Strategy? Get shots in arms.

About half of American adults plan not to get a flu shot this year; everyone is tired of COVID talk and prevention; but flu is brewing in the southern hemisphere, Ransone says.

Your daily dose of clinical news from Patient Care Online.

The investigational respiratory syncytial virus vaccine had an overall efficacy of 82.6% against RSV-LRTD, 94.6% against severe disease, and 94.1% in adults with comorbidities.

A large cohort study confirms the observed efficacy of initial and follow-up COVID-19 vaccination and prior infection against infection, hospitalization, and death.

Elizabeth Sapey, PhD, discusses how the updated treatment recommendations from the World Health Organization may impact future use of remdesivir.

Elizabeth Sapey, PhD, discusses findings from the SOLIDARITY study and similar research on the efficacy of remdesivir for treatment of severe disease.

Influenza rates were higher in Australia during the April-October season this year than they have been in 5 years. Should we be preparing now?

Elizabeth Sapey, PhD, discusses the updated recommendations and the research that prompted the decision.

Refractory adult misbeliefs about vaccine safety have increased reluctance to vaccinate US children aged 5-11 years, according to an Annenberg Public Policy center survey.

This influenza antiviral brush-up slide show reminds you of key features of the 4 FDA-recommended medications, at-a-glance.

WHO: Evidence is lacking for clinical effectiveness of Xevudy and Regen-Cov against the COVID-19 variants that are currently circulating.

Data from the CDC on US vaccination and booster shot rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

Data from the CDC on US vaccination and booster shot rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.